TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cognitive function assessments (memory, executive functions, attention/mental speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peak post-ischemic blood flow in the arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver function markers (γ-glutamyl transferase, aspartate transaminase, soluble tumor necrosis factor α receptor 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold-Response Index (CRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: annualized rates of moderate/severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time-to-first moderate/severe exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean number of ventilator-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c levels <= 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL levels < 2.5 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: osseous fusion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride levels during EPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estradiol levels during EPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VAS score of 2nd menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rates of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated serum CRP (above 3 mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of CTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical success rate at 21 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory bacteriological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: treatment related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the lamina reticularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in Kaposi's sarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy in hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICIQ-UI SF score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of gastric volume waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MSTS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TESS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 bodily pain score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic yield for gastric SET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Limb fat increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trunk fat increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose level elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention rate of sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries lesions incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NVRS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal MDA at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal TAS at 10 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duodenal polyp burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleeding points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total clamp time (minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: nodule detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skinfold measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postponement of water and/or tea intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mu-opioid receptor BP in the left inferior temporal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: negative affect ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative opioid requirement for rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients that relapsed
Endpoint domain: Mortality/survival
Primary endpoint: QTcI change compared with placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness of the plantar fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypoechoic fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T staging accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N staging accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment plan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to threshold ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Successful iridectomies at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of iris bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in IOP > 10 mm Hg
Endpoint domain: Adverse events/effects
Primary endpoint: Reducing TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive child behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Seizure freedom for at least 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates in different epilepsy types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation due to intolerable side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative LV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Brief Psychiatric Rating Scale Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of extrapyramidal side effects (EPS)
Endpoint domain: Adverse events/effects
Primary endpoint: all-cause death at five years
Endpoint domain: Mortality/survival
Primary endpoint: Chronic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postoperative BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improving life quality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of DR intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SF-36 total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Org9426 infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in coagulation and fibrinolytic systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum IFN‐γ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analog Scale (VAS) pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional disability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the FVAQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil major basic protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IOP rise prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of medications required to maintain IOP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: POBF (Posterior Ocular Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP (Intraocular Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physical activity at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary changes at 12 and/or 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with cancer-related care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time to completion of primary cancer treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 mental score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EASPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean health care costs attributed to spinal pain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: WOMAC scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36 BP scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline for ICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline for ACD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia grades
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for redilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 and ED50 values for phenylephrine and norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative potency ratio of norepinephrine to phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of dropouts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of omission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peak acyclovir plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily area under the curve values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of remaining free from treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Mean time in 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach target MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Odds of reaching MAP of 107 mmHg or less within 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in body image
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Major change in primary diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verification of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional important diagnosis made
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of a generic switch
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient-reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average weekly alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of abstinent days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SADD scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antibody persistence (seroprotection and concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postbooster seroprotection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: glycosylated hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-hour postprandial plasma glucose (2hPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of psychosocial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowest systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hypotensive episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Median percentage reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Decrease in PARS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical symptoms of selenium overload (selenosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Selenium intake levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean glucose excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrusion of upper incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protrusion of lower incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual field (VF) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity (VA) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms of Kidney Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in blood alkaline phosphatase and beta 2‐microglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indoor allergen levels below threshold for sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength (BS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohesive fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Risky driving inclinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk-positive emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin sensitivity (ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAI-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4/CD8 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regression of PDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of CRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of CRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in self-harm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms of depression and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-esteem improvements
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MCE risk classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HOOS pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HOOS function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ASI drug composites improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pathologic socket angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dorsoplantar inclination angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteroposterior inclination angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCP joint space improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in OHIP-EDENT scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the mandibular denture
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incremental Cost-Effectiveness Ratio (ICER) per QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healing period duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration of sildenafil (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes